Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Eagle Pharmaceuticals excels in 2022 with strong earnings growth

Eagle Pharmaceuticals' 2022 performance reflects strong earnings growth and operational efficiency, supported by key product sales and financial stability.
While facing challenges in managing expenses amidst investments, the company's strategic strengths lie in its product portfolio and financial resilience.
Opportunities for revenue growth and market expansion present avenues for Eagle Pharmaceuticals to further enhance its competitive position and drive future success.

Eagle Pharmaceuticals posts robust Q1 results, eyes strategic growth opportunities

Eagle Pharmaceuticals delivered a strong financial performance in Q1 2023, driven by key product sales and market share retention.
While facing challenges in expenses management, the company's solid cash position and growth strategies position it well for future opportunities.
Strategic initiatives like potential acquisitions and market expansion underscore Eagle Pharmaceuticals' commitment to sustained growth and innovation.

Eagle Pharmaceuticals beats Q2 estimates, eyes growth through strategic investments

Eagle Pharmaceuticals delivered a robust Q2 performance, exceeding expectations and demonstrating strong financial health. The company's strategic investments in R&D and commercial infrastructure position it well for future growth. Despite challenges and uncertainties, Eagle Pharmaceuticals remains optimistic about its continued growth trajectory and market prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 2, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, Brian Cahill, Chief Financial Officer, senior members of Eagle's executive leadership team, and other distinguished external speakers will host a 90- minute conference call as follows: Date Tuesda

Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021

The FDA has issued a complete response letter (CRL) for Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) abbreviated marketing application seeking vasopressin approval.

FDA Rejects Eagle Pharma's Vasopressin Application

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA within 30 days. Importantly, Eagle has completed an extensive amount of developmental work and continu

Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 29, 2021, the United States District Court for the District of Delaware (the “Court”) postponed the February 1, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. The Court expects to hold a call with the parties today to discuss a new trial date. Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals, stated, “Par'

Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed

NEWARK, N.J., Jan. 28, 2021 /PRNewswire/ -- SEEDS – Access Changes Everything (SEEDS) is pleased to announce a new, multi-year partnership with Eagle Pharmaceuticals that will provide educational funding for 12 high-achieving students over the course of two years, while also supporting...

SEEDS - Access Changes Everything Announces Multi-Year Partnership with Eagle Pharmaceuticals

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is exp

Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference as follows: Date: Wednesday, January 13, 2021 Time: 4:30 p.m. Eastern Standard Time Webcast: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35699-eagle-pharmaceuticals/webcast?gpu_only=true&kiosk=true

Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company's pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference is now available for viewing via the link below: https://pipersandler.zoom.us/rec/play/0TlXfXVGZ3QG7IgEE4PyzFEfiG8HyD57XqSaO9Uq1Rsb_J29jmyS2ZvqWskPC1MJPA_AP6kFUMjJQfFd.vyuNfKmJI0FvhIOg It is also available on the Company's website at www.eagleus.com, under the Inves

Eagle Pharmaceuticals' Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2020 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 303.45% and 7.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Beats Q3 Earnings and Revenue Estimates

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020. Business and Recent Highlights: Received formal notification from FDA granting Priority Review for the Company's abbreviated new drug application (“ANDA”) filed for vasopressin. A trial date of January 11, 2021 has been set; Added four experienced pharmaceutical industry executives to clinical, form

Eagle Pharmaceuticals Reports Third Quarter 2020 Results

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced four additions to its clinical, formulations and commercialization leadership teams: Judith (“Judi”) Ng-Cashin, M.D., is EVP and Chief Medical Officer; John Kimmet, is EVP, Oncology and Acute Care Marketing; Valentin R. Curt, M.D. is SVP, Clinical Drug Development; and Gaozhong Zhu, Ph.D., is SVP, Pharmaceutical Development. Dr. Ng-Cashin, Mr. Kimmet, Dr. Curt, and Dr. Zh

Eagle Pharmaceuticals Strengthens Management Team to Prepare for Future Growth

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Monday, November 2, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Monday, November 2, 2020 Time 8:30 a.m. ET Toll free (U.S.) 866-342-8591 International 203-518-9713

Eagle Pharmaceuticals to Discuss Third Quarter 2020 Financial Results on November 2, 2020

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its Board of Directors has approved a $25 million accelerated share repurchase (“ASR”) transaction with JPMorgan Chase Bank, National Association (“JP Morgan”) as part of the Company’s existing $160 million share repurchase program. The specific number of shares to be repurchased pursuant to the ASR is based on the average of the daily volume weighted average share p

Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner, SymBio Pharmaceuticals Limited (“SymBio”), has received regulatory approval for TREAKISYM ready-to-dilute (“RTD”) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan. The approval covers all indications for which TREAKISYM is currently approved (low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma

Eagle Pharmaceuticals’ Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute (“RTD”) Formulation, with Launch Expected in January 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals to Present at Upcoming September 2020 Healthcare Conferences

Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer’s Disease

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2020 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates

Eagle Pharmaceuticals Reports Second Quarter 2020 Results

Eagle Pharmaceuticals to Discuss Second Quarter 2020 Financial Results on August 10, 2020

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code for PEMFEXY™ (pemetrexed for injection). This new Healthcare Common Procedure Coding System (HCPCS) code, or J-code, is J9304 (Injection, pemetrexed (PEMFEXY), 10 mg). The J-code will become effective on October 1, 2020. The new HCPCS code provides coding cl

CMS Establishes Unique J-Code for Eagle Pharmaceuticals’ PEMFEXY™ (Pemetrexed for Injection)

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2020 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected at $55.02 after the company reported Q1 results.

News for Eagle Pharmaceuticals Stock (EGRX)